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Field cancerization denotes the occurrence of genetic, epigenetic, and biochemical aberrations in structurally intact cells in histo-
logically normal tissues adjacent to cancerous lesions. This paper tabulates markers of prostate ﬁeld cancerization known to date
and discusses their potential clinical value in the analysis of prostate biopsies, including diagnosis, monitoring progression during
active surveillance, and assessing eﬃcacy of presurgical neoadjuvant and focal therapeutic interventions.
1.Introduction
1.1. Deﬁnitions of Field Cancerization. The term “ﬁeld can-
ceriza-tion” or “ﬁeld eﬀect” was originally introduced by Dr.
Slaughter and colleagues in 1953 in the context of oral
squamous cell carcinoma [1]. It was used to describe the
presence of histologically abnormal tissue surrounding pri-
marycancerouslesionsandwasproposedtobethereasonfor
theoccurrenceofmultifocaltumorsandforthedevelopment
of locally recurrent cancer. Field cancerization was much
later proposed for other organ systems, including prostate
[2–7]. While its original clinical implication remained the
same, that is, the occurrence of multifocality and cancer
recurrence, it must be emphasized that the deﬁnition of ﬁeld
cancerization has changed over time. Of note, due to the
tremendous progress in molecular biology and biotechnolo-
gy since the 1950s, the description of ﬁeld cancerization has
changedfromalargelyhistologicaltoamorereﬁnedmolecu-
lar perspective. This change is perhaps best reﬂected in the
following deﬁnitions reported in the literature. Accordingly,
the original intention by Slaughter and colleagues [1]w a st o
describe: “The presence of histologically abnormal tissue sur-
rounding cancerous lesions.” H¨ ockel and Dornh¨ ofer extended
this deﬁnition by using the term “hydra phenomenon of
cancer” [8]: “The monoclonal or multiclonal displacement of
normal epithelium by a genetically altered but microscopically
undistinguishable homologue.” In addition to the transition
from a purely histological to a molecular description, anoth-
er notable change is the introduction of the concept of
histological normalcy as part of tissue pre-malignancy. In-
deed, this newer deﬁnition is now established for organs de-
velopingsolidtumors,includingprostatecancer,anddenotes
the occurrence of molecular alterations in structurally intact
cells that are part of histologically normal tissues.
Several aspects of prostate ﬁeld cancerization remain un-
answered. An immediate question is whether the “ﬁeld” of
molecular alterations is exclusively of precursor nature, or
whether it is induced by the tumor. This is further compli-
cated by the fact that this inﬂuence could aﬀect all types of
cells,including cellsof thestroma.Thelatterhasindeed been
discussed as “reactive stroma”, which develops to support, or
eveninduceoncogenesisandcancerprogression[9,10].This
heterotypic view has recently been proposed in the context
of the tissue organization ﬁeld theory as opposed to the well-
established somatic mutation theory [11].
1.2. Prostate Field Cancerization and Multifocality. Prostate
cancer tends to present as multifocal disease with reported
rates of up to 90% of prostates containing two or morecan-
cerousfociatthetimeofclinicaldiagnosis[12].Multifocality2 Prostate Cancer
is viewed as a major contributor to the complexity and
inaccuracyofallaspectsofprostatecancerclinicalassessment
and management [12–15]. For example, it greatly compli-
cates staging and grading because individual foci usually
display extensive heterogeneity and thus could progress at
diﬀerent rates depending on the nature and extent of their
genetic instability and their microenvironment. Fortunately,
some of these challenges can be partially counteracted
by sophisticated histological assessments, for example, the
Gleason sum score which combines the ﬁrst most common
with the second most common grade of dediﬀerentiation,
enhances the accuracy of prognosis and patient outcome and
consequently deﬁnes the most optimal treatment modality
[16].
Severalmechanismsunderlying thedevelopment ofmul-
tifocality can be envisioned. Accordingly, diﬀerent cancerous
foci could evolve truly independently from each other; they
can remain isolated or fuse if they are in close proximity to
each other. The latter would explain the existence of diﬀerent
gradesofdediﬀerentiation often found within one lesion, for
example,theconcomitantoccurrenceofthecancerprecursor
prostatic intraepithelial neoplasia (PIN) with cancer of
diﬀerent Gleason grades [6, 17]. Alternatively, multifocality
couldbeexplainedbyintraductalmigratorycellsundergoing
dysplasia; in this case, intrafocal heterogeneity could be due
to concomitant development of diﬀerent genetic aberrations
of diﬀerent cell clones of an individual lesion. It is not
inconceivable that prostate cancer multifocality could be due
to a combination of these mechanisms occurring concomi-
tantly. Regardless of the mechanisms that lead to prostate
cancer multifocality, it is compatible with the concept of
ﬁeld cancerization. In fact, a ﬁeld eﬀect, deﬁned as an
underlying “predisposition” in areas of the prostate gland,
has been proposed to play a causal role in the development
of multifocal lesions [6, 12].
2. FieldCancerization: Possible
ApplicationsinProstateBiopsies
The necessity to recover tissue from the prostate gland by
transrectalortransperitonealbiopsycanbeindicatedforsev-
eral reasons, including conﬁrmatory diagnosis, monitoring
progression during active surveillance, and assessing eﬃcacy
of presurgical neoadjuvant and focal therapeutic interven-
tions. In this paper, we will make a case for the potential
clinical value of ﬁeld cancerization to several applications
involving the use of biopsies. In particular, we will discuss
the possibility that speciﬁc markers of ﬁeld cancerization
could be useful and complementary biomarkers for the
accurate clinical assessment of prostate biopsy tissues. At
least three excellent recent reviews have provided lists of
molecular factors that are indicative of ﬁeld cancerization
in human prostate tissues [3–5]. Although research on ﬁeld
cancerization in prostate tissue is relatively new compared
to other organ systems, including head and neck as well as
breast [18, 19], this list has become quite impressive due to
the increasing acceptance of this concept. To fully appreciate
the diversity of markers of prostate ﬁeld cancerization, we
provide here an updated overview, inclusive of stromal
markersthatﬁtthedeﬁnitionofﬁeldcancerization(Table 1).
This list emphasizes at least two important insights into
the biology of ﬁeld cancerization in prostate tissues: ﬁrst,
ﬁeld cancerization is manifested at all levels of the biological
information ﬂow and molecular regulation, that is, at the
genetic, epigenetic, transcriptional, and posttranscriptional
level.Second,ﬁeldcancerizationencompassesseveralcellular
processes, including proliferation, metabolism, inﬂamma-
tion, DNA repair, and stromal/epithelial interactions. In
theory, these broad biological characteristics of prostate ﬁeld
cancerization should increase the potential clinical value of
its markers, especially when used in combination with other
clinically established indicators.
The clinical use, as speciﬁcally applied to prostate
biopsies that could greatly beneﬁt from well-characterized
markers of ﬁeld cancerization are discussed in the fol-
lowing sections. The markers of prostate ﬁeld canceriza-
tion listed in Table 1 were extracted from the literature
published in the PubMed database of the US National
Library of Medicine of the National Institutes of Health
(http://www.ncbi.nlm.nih.gov/pubmed/). The following key
words were used in multiple combinations: “(bio)markers,
prostate, biopsy, histologically normal, adjacent, ﬁeld can-
cerization, ﬁeld eﬀect, diagnosis, prognosis, margins, active
surveillance, neo-adjuvant therapy, and focal therapy.” Of
note, the focused analysis of tissue adjacent to tumors in
general is rare, as it is most often used as a mere control
for analyses speciﬁc to the tumors [20]. Furthermore, the
use of the terms “ﬁeld cancerization” or “ﬁeld eﬀect” is
new in prostate cancer research. Therefore, it is expected
that some reports addressing such analyses may be missing
herein. However, rather than providing a complete list of
possible markers of ﬁeld cancerization and details about
their ﬁndings, we emphasize in this paper their potential as
biomarkers in prostate biopsies.
2.1. Prostate Field Cancerization and Diagnosis. The risk of
having prostate cancer is currently assessed by the triad
of elevated serum prostate speciﬁc antigen (PSA; typically
≥3ng/mL), abnormal digital rectal examination (DRE), and
transrectal ultrasonography (TRUS) [21]. However, these
indicators are per se not suﬃcient for the accurate diagnosis
of cancer because of low sensitivity (especially for DRE and
TRUS) and speciﬁcity (especially for PSA) [22, 23]. Rather,
they justify the patient’s referral to the removal of biopsy
cores for conﬁrmatory diagnosis of cancer by histological
assessment [21, 24]. Despite substantial controversy (further
discussed in Section 2.2), PSA and DRE are often used to
screen for prostate cancer leading to millions of analyzed
needle biopsies each year in the USA [21, 24, 25]. A major
problem inherent to biopsies is that 30–50% of men with
subsequently conﬁrmed prostate cancer experience an initial
false-negative diagnosis [25–27]. This is because biopsy core
needles can easily miss smaller and inconspicuous lesions
(Figure 1). Conceptually, it seems logical that this problem
relates to the number of biopsies removed. However, the
ideal number of biopsies necessary to accurately detect oneProstate Cancer 3
Table 1: Molecular markers that are in accordance with the deﬁnition of prostate ﬁeld cancerization reported in the literature1.
Type of molecular
alteration2 Speciﬁc molecular marker Reference3
Cytomorphological
changes
Nuclear chromatin structure [34]
Nuclear chromatin structure [35]
Nuclear texture [36]
Epigenetic changes
Methylation of GSTp1 and RARβ2[ 37]4
Methylation of GSTp1, RARβ2, and APC [38]
Methylation of RASSF1A [39]
Methylation of RARβ2, APC, and RASSF1A [40]
Methylation of HIN-1 [41]
Genomic DNA changes
Proﬁle of infrared spectroscopy [42]
Proﬁle of infrared spectroscopy [43]
Proﬁle of infrared spectroscopy [44]
Telomere attrition [45]
Telomere attrition [46]
TMPRSS2-ERG fusion [47]
Content of DNA [32]
Telomere attrition [48]
Telomere attrition [49]
Telomere attrition [50]4
Mitochondrial DNA
changes
Mutation [51]
Deletion [52]
Deletion [53]
Gene expression changes
Gene expression signature (671 genes) [54]
cDNA microarrays (12,625 probes) [55]
Noncoding RNA from PCA3 gene [56]
Panel of 8 genes [57]
Gene fusion transcript of TMPRSS2-ERG [58]
cDNA microarrays (37,123 probes) [59]
PSCA [60]
Protein expression changes
PS2 [61]
Androgen receptor [62]4
COX-2 [63]
Androgen receptor [64]4
Phosphorylated Akt-1 [65]
EPCA [66]
EPCA [67]
Calcium channel P2X7 [33]
AMACR [68]
Ki67 and MCM-2 [69]
Activated Akt [70]
EPCA [71]
AMACR [72]
β-catenin [73]
Androgen receptor [74]4
Expression of Akt [75]
PDGFRβ [76]4
Phosporylated EGFR [77]4 Prostate Cancer
Table 1: Continued.
Type of molecular
alteration2 Speciﬁc molecular marker Reference3
EGR-1 and IGF1R [78]
UDP-glucose dehydrogenase [79]
Prostate tumor overexpressed 1 [80]
EGR-1 and FAS [81]
NMR spectra Metabolites [82]
1Combined and updated from Nonn et al., 2009 [5] and Halin et al., 2011 [4].
2Additional markers of ﬁeld cancerization that are not strictly molecular in nature, but rather represent cellular changes or adaptations to the presence of the
tumor are cell morphological architecture [83], increased numbers of mast cells and macrophages [84–86], and enhanced microvessel density [87, 88].
3Within a type of molecular alteration group, the studies are reported in chronological order; references are original articles only; additional review articles
are listed in the text.
4Reported in stromal cells.
or more cancer foci has been a controversial issue and
has changed in the modern biopsy era. Under ultrasound
guidance, 6 total cores were ﬁrst recommended, three from
each side of the prostate gland; this was termed “sextant
biopsy.” In the late 1990s, this recommendation was changed
to 10–12 cores taken from the mid and lateral peripheral
zones because it was shown to increase cancer detection [28,
29]. However, since the problem of a high false-negative rate
persisted, the concept of “saturation biopsy” was introduced
thereafter [28, 30]. Saturation biopsy involves removing 20
to 40 cores, and its value for cancer detection is being
investigated as both an initial procedure and as a secondary
intervention (with a focus on lateral and apical cores; also
see Section 2.4) for patients with negative initial biopsy but
persistent elevated serum PSA levels. These patients are by
deﬁnition at a higher risk of having cancer [28]. Regardless
of the number of needle cores removed, a false-negative
ﬁnding, either at ﬁrst or subsequent biopsy, represents an
important problem because it generates anxiety for the
patient and represents a dilemma for the physician as
to whether and what kind of further action is required,
especially in the presence of persistently high PSA [27–29].
Furthermore, an increased number of biopsy cores present
the possibility of more complications and discomfort for the
patient.
The biological nature of ﬁeld cancerization oﬀers a po-
tential means towards an improvement of this problem. The
occurrence of molecular alterations that are associated with
the presence of cancerous lesions, but that are not necessarily
locatedinthesametissuearea,potentiallyincreasesthetarget
region of interest that can provide clinically meaningful
information (Figure 1). This statement applies to both the
traditional sextant biopsy, typically performed in the para-
sagittal plane between the lateral border and midline on both
the right and left sides of the prostate gland as well as to the
extended mode with cores removed more laterally in the
anteriorhornsoftheperipheralzone[30].Dependingonthe
nature of the ﬁeld, that is, its extent and intensity, and on the
discriminatorypowerofthemarker(s)underinvestigation,it
is not inconceivable that the necessity to detect histologically
abnormal tissue or cells could become less important,
especially when such markers are used in combination with
other disease indicators such as PSA. The diagnostic value of
markers of ﬁeld cancerization is ideally tested in nested
case-control studies, either prospectively or retrospectively.
In this design, cases and controls are deﬁned as patients
with initially positive and negative biopsies, respectively.
Retrospective studies oﬀer many advantages with respect to
the control of confounding factors: (i) patients derived from
the same cohort can, and should be age-matched to control
for potentially age related eﬀects; (ii) the date of biopsy re-
moval for cases and controls can be matched to account for
changes in tissue quality over time; (iii) controls who re-
mained free of cancer can be matched with cases who were at
risk during the same time to assure the equal likelihood of
cancer detection, which can be greatly confounded by many
variables after an initial negative biopsy. This approach is
termed“incidencedensitycontrolsampling.”Whenproperly
designed, such optimizations lead to the determination of
odds ratios that are accurate reﬂections of the true relative
risk of having prostate cancer, as either determined at initial
or after repeat negative biopsy (Figure 2)[ 5, 31]. Several
of the factors listed in Table 1, when measured in negative
biopsies, have been shown to predict the presence of cancer
at prostatectomy (e.g., [32, 33]), indicating that all such
markers have this diagnostic potential.
2.2. Prostate Field Cancerization and Prognosis. T h et i m eo f
biopsyconceptuallyrepresentsanidealpresurgicalsettingfor
clinical decision making for a patient at risk of having pros-
tate cancer. However, even if the diagnosis of cancer can
be achieved with high accuracy, a second related and as
yet unresolved problem emerges at this point, that is, prog-
nosis. While prognosis of progression is particularly power-
ful after surgical intervention, when the full extent of multi-
focality, distribution of grade, clinical staging (e.g., tumor
volume), and analysis of surgical margins can be thoroughly
performed, such assessment is much less accurate and often
impossible in biopsies. Nevertheless, there is a growing con-
sent among urologists that the detection of cancers in bio-
psies must be accompanied by the ability to determine the
course of disease [16, 25]. Such conclusions are strongly sup-
ported by the large randomized trials of prostate cancer
screening using the serum PSA test, that is, the Euro-
pean Randomized Study of Screening for Prostate CancerProstate Cancer 5
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Figure 1: Improved diagnosis of prostate cancer by avoiding false negative biopsies through the use of markers of ﬁeld cancerization. Biopsy
cores (small circles) miss the two small cancer foci (white irregular structures; left); the ﬁeld associated with the cancer foci (dashed circles)
is detected by the biopsies (right).
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Figure 2: Nested case-control study design to investigate the diagnostic and prognostic potential of markers of ﬁeld cancerization (FC) at
the time of biopsy. Discrimination between positive and negative (or aﬀected by benign prostatic hyperplasia, BPH) initial or repeat biopsies
tests whether FC predicts the presence of cancer (left grey box). Discrimination between subsequently negative and positive biopsies after
initial or repeat negative biopsies tests whether FC predicts development of cancer (bottom grey box). Prediction of cancer progression in
initially positive biopsies indicating low-risk cancer during active surveillance tests whether FC is prognostic (top grey box).
(ERSPC) and the American Prostate, Lung, Colorectal, and
Ovarian (PLCO) Cancer Screening Trial. Although the
primary focus of these studies was to study the association
between screening and mortality, they also showed that
the accompanying increased rate of cancer detection (70%
and 22% higher in the ERSPC and PLCO, resp.) did not
substantially improve mortality rates [89, 90]. These results
show that diagnosis and prognosis are closely interrelated is-
sues and ideally, should not be addressed separately. In fact,
it is now recognized that increasing detection of cancer in
biopsies without the ability of being able to discrimi-
nate between aggressive and indolent disease can lead to
the clinical overtreatment of patients who may remain
asymptomatic throughout their lifetimes. Such patients
may experience unnecessary treatment at a high cost-to-
beneﬁt ratio, including a lower quality of life, and would
beneﬁt more from active surveillance programs [91] (further
discussed in Section 2.3). Although often problematic and
controversial, staging and grading information for prognosis
is routinely assessed in biopsy tissue. For example, all biopsy
cores containing cancerous tissue are analyzed for their
level of de-diﬀerentiation by assigning a Gleason grade. In
addition, parameters such as the number of cores aﬀected
by cancer, and within a single core, the percentage of tissue
aﬀected by cancer as well as the location (especially at the
apex for saturation biopsies) are used to predict tumor
focality, size, and extracapsular extension which are classical
staging parameters [16, 25]. However, the assessment of
theseparametersinbiopsytissuesisfrequentlycompromised
by mischaracterization of the cancer. This is evidenced by
the persistent problem of stage and grade migration after
prostatectomy [25].
Aswithdiagnosis,markersofﬁeldcancerizationcouldbe
helpful to predict the course of disease. In fact, it is well
accepted that the entire microenvironment, including stro-
mal cells, extracellular matrix, and growth factors is a critical
determinant of tumor cell behavior for most cancers [92]. In
prostate cancer, the microenvironment has even been shown
to be a controlling factor and key driver of tumor initiation
and progression [93]. Importantly, the interaction between
tumor cells and its associated stroma not only pertains to the
tumorareaitself,butextendstoareassurroundingthetumor
at an increased distance. This implies that characteristic
m a r k e r so ft u m o ra d j a c e n tt i s s u e sh a v ep r e d i c t i v ev a l u ei n
determining tumor initiation or progression. Such markers
could be highly informative in both initially negative and
positive biopsies (Figure 2). In negative cases, even after
repeat biopsies, these markers could indicate whether6 Prostate Cancer
adenocarcinoma develops subsequently. The value of these
markers in initially positive biopsies from men with low-risk
cancer is discussed in the next section in the context of active
surveillance.
2.3. Prostate Field Cancerizationand Active Surveillance. One
option for the management of low-grade (Gleason score of
≤6) and low-stage (T1c or T2a) prostate cancer with PSA
levels of ≤10ng/mL is to delay or forego more aggressive
treatment unless evidence of an increased risk of disease
progression exists. This approach is called active surveillance
and aims at avoiding the substantial side eﬀects that accom-
pany radical prostatectomy and radiation therapy, such as
incontinence, impotence, and bowel dysfunction [89–91].
Active surveillance includes monitoring the patient’s cancer
with PSA tests and digital rectal examinations every 3–
6 months, and performing prostate biopsies every 12–24
months. The optimal strategy for the latter seems to be
the “staging saturation biopsy” approach to monitor the
possibility of pathological upgrading and clinical upstaging
[25, 28].
Conceptually, the statements made earlier about the
potential of markers of ﬁeld cancerization to indicate a pos-
sible progression towards increased malignancy apply here,
too. It can be easily acknowledged that the longer-term mon-
itoring approach which is at the heart of active surveillance
is ideal to determine indicative and clinically meaningful
changes over time (Figure 2). Regardless of whether such
molecular changes in histologically intact tissues indicate
progressive instability towards further cancer development,
or whether they reﬂect the inﬂuence of a new or already
existing and progressing tumor, a marker that can be
assessed dynamically and quantitatively over time with high
resolution would be of great value. Lastly, because saturation
biopsy covers a larger area of the prostate gland, the
concerted information from several biopsy cores can be used
to identify possible “geographical patterns” of molecular
alterations and their change over time. Since research on
prostate ﬁeld cancerization is new, it has not been applied to
speciﬁc clinical scenarios such as active surveillance. Speciﬁc
examples of such markers in this particular setting are thus
missing from the literature. However, the feasibility for the
prognostic potential of markers of ﬁeld cancerization is
greatly supported by the fact that several of the factors listed
in Table 1 have been shown (partly in biopsies) to correlate
with adverse patient outcome, such as biochemical (PSA)
recurrence after radical prostatectomy [48, 65].
2.4. Prostate Field Cancerization and Preoperative Assessment
of Positive Margins. A positive surgical margin is deﬁned as
tumor cells touching the inked edge of the specimen. This
ﬁnding is reported in approximately 25% of cases. Positive
margins are one of the main determinants of biochemical
(PSA) relapse and are associated with a doubled or tripled
risk of failure, depending on their number and location
at the inked edge [94]. Ideal prognostication of margin
status would entail preoperative and highly informative
biopsies to predict the risk of a positive surgical margin
and as a consequence, an extraprostatic extension at radical
prostatectomy.Infact,preoperativeknowledgeaboutmargin
status, combined with other indicators of aggressiveness
determined at the time of biopsy could greatly inﬂuence the
choice of further intervention. To explore this possibility,
the deliberate positioning of biopsy cores for tissue removal
at the apex or the base, and their association with positive
margins at the time of prostatectomy were previously
investigated [95–98]. Interestingly, these investigations tend
to be inconclusive with diﬀerent studies reporting diﬀerent
outcomes. When individual core apical biopsies containing
cancer were queried for their predictive value of positive
surgical margin status and tumor involvement at the apex, it
was less than 30% [97]. Similar results were reported when
the incidences of a positive margin at both the apex and
the base of the gland were analyzed for their association
with the detection of positive or negative apical or basal
biopsies [95]. In contrast, other studies determined the
independent prognostic capability of positive preoperative
apical biopsies for predicting positive surgical margins at the
apex and reported positive predictive values of >70% [96].
Yet another study [98] reported conﬂicting results between
apical and basal positive biopsies as predictors of positive
surgical margins and extraprostatic extension. In this study,
a positive biopsy at the base, but not at the apex, was
predictive of a positive surgical margin and extraprostatic
tumor involvement. Collectively, these studies show that the
clinical value of preoperative analysis of apically and basally
positioned biopsy needle cores to predict margin status
remains inconclusive.
If markers of ﬁeld cancerization are indicators of
increaseddiseasestatus,orindicatorsofextraprostaticcancer
presence, it can be acknowledged that they could contribute
to a more molecular and more reﬁned interpretation of api-
cal and basal biopsy material. Because research on prostate
ﬁeld cancerization is relatively new, examples speciﬁc to
the assessment of positive margins are missing from the
literature. However, the feasibility of such investigations has
been announced [40], and given the importance of the zonal
origin of biopsy cores taken from geographically distinct
areas of the gland [99], it can be inferred from the studies
on a variety of factors listed in Table 1.
2.5. Prostate Field Cancerization and Neo-Adjuvant Therapies.
Neo-adjuvant intervention for prostate tumors is mostly
indicated for high risk but localized organ-conﬁned cancer.
It can be applied as a monotherapeutic or multimodality
approach and can entail radiotherapy, androgen ablation
therapy, and chemotherapy [100]. The major goal of pre-
surgical neo-adjuvant approaches is to improve the long-
term outcome of subsequent prostatectomy with curative
intent,ashasbeenshownforallofthemodalitieslistedabove
[101, 102]. An additional value of neo-adjuvant intervention
is that it provides an opportunity for evaluating the activity
and mechanism of action of neo-adjuvant new agents in
correlative phase II clinical studies (Figure 3).
With respect to the latter, well-validated markers of
ﬁeld cancerization could function as surrogate endpoint
indicators of therapeutic eﬃcacy in biopsies removed before
and after therapeutic intervention. Even when guided byProstate Cancer 7
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Figure 3: Study design to investigate the predictive potential
of markers of ﬁeld cancerization for pre-surgical neo-adjuvant
therapies (black box), including the testing of novel agents in
phase II clinical studies. Instead of applying surgical treatment with
curative intent as a consequence of diagnosis of cancer at biopsy
(whiteboxes),markersofﬁeldcancerizationareassessedatthetime
of biopsy and after neo-adjuvant therapy (grey boxes) to determine
its eﬃcacy.
ultrasound or other imaging techniques, it would be
extremely diﬃcult if not impossible to reliably resample
the same premalignant tissue area in order to assess the
eﬀect of the therapeutic intervention. This is where markers
of ﬁeld cancerization could have a special advantage over
markers that are speciﬁc for cancerous cells because they
wouldbedetectedandquantitativelyvalidatedinstructurally
intact cells residing in histologically normal tissue associated
with the lesion. In addition, assuming that the ﬁeld is
larger than the lesion itself (also see Figure 1), the exact
position of the needle core biopsy would not matter as
long as it is in the vicinity or area of the cancerous focus.
Furthermore, as for most applications discussed in this
paper, this possibility would be independent of whether the
molecular alterations under investigation are precursors of
the cancer or merely induced by its presence, as long as
the ﬁeld is representative of the tumor’s response to the
therapeutic intervention. Reports on speciﬁc examples of
markers of ﬁeld cancerization applied to the validation of
neo-adjuvant therapies are missing from the literature, but
are expected to increase once distinct molecular markers
have been better characterized and validated.
2.6. Prostate Field Cancerization and Focal Therapy. Organ-
preserving therapy is widely accepted for several types of
tumors where the lesions are found to be small, well-
diﬀerentiated, and conﬁned. Organ sparing approaches
includepartialasopposedtoradicalresection,aswellasfocal
treatment by cryotherapy, laser ablation, and high-intensity
focused ultrasound. The obvious goal is to speciﬁcally
destroy cancerous tissue areas while leaving the majority
of the organ and the surrounding tissues unscathed and
functional, and thereby avoiding substantial side eﬀects and
reduced quality of life accompanying radical prostatectomy
[103, 104]. Because of the tendency to present with mul-
tifocal disease (see Section 1.2 above), focal therapy was
not considered suitable for prostate cancer. However, several
reasons have shifted this view towards a more favorable
one. For example, the very essence of active surveillance
(described in Section 2.3) is based on the notion that most
lesions within a gland are indolent in nature and will not
progress. Coupled with ever improving imaging and energy-
delivery techniques, it is becoming increasingly feasible to
detect and treat the primary (index) lesion. While the latter
approach bears the risk of ignoring smaller yet potentially
more aggressive lesions, it does nevertheless oﬀer additional
tumor control for patients choosing active surveillance.
However, the beneﬁts of focal intervention will have to
be determined in large trials before this approach can be
recommended in all men with low-risk progression prostate
cancer.
The biology of ﬁeld cancerization conceptually opposes
the use of focal therapy for the treatment of prostate cancer
becausetheattemptederadicationofhistologicallycancerous
tissue would leave behind structurally intact yet molecu-
larly altered and genetically compromised tissues that may
contain cells with the potential to cause onsite recurrences
and/or secondary tumors (Figure 4). However, at least three
deviations from this view should be mentioned. First, if
markers of ﬁeld cancerization are able to discriminate
with high accuracy histologically normal yet genetically
compromised (i.e., ﬁeld cancerized) from histologically and
genetically intact (i.e., truly normal) tissues, the extent of
the ﬁeld associated with an individual lesion would become
deﬁned and could be included in the focal therapeutic
approach(Figure 4).Second,ifmarkersofﬁeldcancerization
are predictive of progression (as discussed in Section 2.2),
indolentlesionscouldbediscriminatedfrommoreaggressive
foci, thereby increasing the eﬃcacy of focal therapy by
guidingittowardsfociwithhigherriskofprogression.Lastly,
if markers of ﬁeld cancerization are merely indicators of
the presence of cancer cells, as opposed to precursors of
disease (as discussed in Section 1.1), they could be of value
as predictive indicators for the eﬃcacy of focal intervention
(similar to their application described in Section 2.5).
3. Conclusions
Prostate cancer is an extensively heterogeneous disease with
highly variable clinical outcome. The time of biopsy is an
important milestone for a patient at risk of having cancer
and progressing to a more advanced stage. Apart from
conﬁrmatory diagnosis, the information gained from biopsy
cores is also crucial in determining further actions, especially
the choice between active surveillance and more aggressive
therapeutic interventions, including radical prostatectomy
(Sections 2.1 to 2.4)[ 25, 105]. The procurement and analysis
of biopsies also play a role during therapeutic intervention,
such as in predicting and monitoring the eﬃcacy of pre-
surgical neo-adjuvant and focal therapy (Sections 2.5 and
2.6)[ 100, 104]. Therefore, the clinical management of
prostate cancer leads to millions of biopsy cores that are
removed by urologists and analyzed by pathologists each8 Prostate Cancer
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Figure 4: A primary tumor (black irregular shape) is associated with a complex ﬁeld of molecular alterations in structurally intact cells in
histologically normal adjacent tissue (arrows and dotted lines; left). After focal therapy to the primary tumor (white dashed lined irregular
shape), premalignant areas (grey irregular shapes) may in time lead to onsite or secondary tumors within the remaining ﬁeld (upper right).
If focal therapy is extended to include the ﬁeld, onsite recurrences could be avoided (lower right).
year in the USA [21, 24, 25], underscoring the importance
of this type of material. Unfortunately, the analysis and
interpretation of prostate biopsies is often complicated by
limiting factors such as the number of cores aﬀected by can-
cer, the amount of glandular tissue in an individual core, and
the amount of tissue in general. In addition, there remains
discordance, despite extended biopsy schemes, between the
interpretation from biopsy material and information gained
at prostatectomy, as evidenced by the frequency of upstaging
and upgrading [25, 28].
Markers of ﬁeld cancerization have the potential to
overcome these important barriers. This is due primarily
to the fact that molecular alterations that deviate from
normalcy can be assessed in a larger target, deﬁned as the
tissue area adjacent to the tumor lesion, thus becoming more
independent of the analysis of the lesion itself. However, key
to such optimization is the choice of the proper controls for
potentially ﬁeld cancerized tissues, as the focus is shifted to
what most investigators use as the control for the analysis of
tumor tissues [20]. Tissues unrelated to cancer and similar
conditions should be chosen and matched for age, body
mass, and other factors to avoid detection of false positive
molecular aberrations. This may be challenging due to inter-
tissue heterogeneity and requires extensive characterization
of the biomarker under investigation with respect to its
association with cancer presence or development. The latter
necessitates detailed knowledge about the nature and extent
of the ﬁeld associated with tumor foci. This knowledge,
however, has just begun to be generated for men at risk of
having or developing prostate cancer. Nevertheless, data in
support of the potential of markers of ﬁeld cancerization to
help solve the “cancer biomarker problem,” as emphasized
recently by leaders in the ﬁeld [21, 106], is accumulating
(Table 1) and warrants further research.
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